EUVIMEDEUVIMED entdecken
LeserbriefVergleichsstudie

Comparison of outcomes of immunosuppressive therapy with rabbit versus horse antithymocyte globulin and cyclosporine a in children with acquired severe aplastic anemia

Ayami Yoshimi iD, Peter Noellke, Jan Starý, Krisztián Kállay, Owen Smith, Franco Locatelli iD, Jochen Buechner, Ivana Bodova, Julian Sevilla, Markus Schmugge, Marc Bierings, Tania Masmas und 10 weitere

American Journal of Hematology · 2024

DOI: 10.1002/ajh.27334 ↗

Kurz gefasst

Leserbrief in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Ayami Yoshimi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, Medical Center, Faculty of Medicine, University of F…. Hauptthemen laut MEDLINE: Antilymphocyte Serum, Anemia, Aplastic, Cyclosporine, Immunosuppressive Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 7 Literaturangaben. Gefördert von: Parent Association in Freiburg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunosuppressive therapy (IST) combining antithymocyte globulin (ATG) and cyclosporine (CSA) is a consolidated therapy for aplastic anemia (AA). Currently, there are two animal sources of ATG available, namely horse (h-ATG) and rabbit (r-ATG) ATG. While the h-ATG Atgam® (Pfizer) continues to be the standard ATG for IST in the US, the h-ATG traditionally used in Europe and Asia, Lymphoglobulin® (Genzyme), was withdrawn from the market in 2007. Since then, first-line therapy in many European and Asian countries consisted of Thymoglobulin® (r-ATG, Sanofi). Several groups reported inferior results of IST with r-ATG compared to those with h-ATG, while comparable results of both ATG were reported by others group.1-3 Importantly, a randomized controlled trial published in 2011 showed an inferior response rate at 6 months (37% vs. 68%, p < .001) and a decreased overall survival (OS) at 2 years (76% vs. 96%, p = .04) in patients in the United States treated with r-ATG (Thymoglobulin®) compared with h-ATG (Atgam®).2 Based on these results, most European centers introduced Atgam® as first line IST, while Thymoglobulin® continues to be applied in countries where h-ATG is not available. Recently, Atgam® has been approved for the treatment of AA in most European countries. Here, we report the outcome of IST with ATG and CSA in 150 children with AA from 19 European countries, who were registered to the European Working Group of Severe Aplastic Anemia (EWOG-SAA) 2010 study between 2011 and 2020 (German Clinical Trials Register: DRKS00000610), comparing h-ATG Atgam® and r-ATG Thymoblobulin®. Our results show that patients treated with h-ATG have better early response, which may be clinically beneficial for patients with AA, while there was no difference in survival between the two ATG groups. One hundred-fifty consecutive patients with AA less than 18 years of age, who received first-line IST with either h-ATG (Atgam®, 40 mg/kg × 4 days, n = 110) or r-ATG (Thymoglobulin®, 3.5 mg/kg × 5 days, n = 40) with at least 180 days follow-up after start of treatment were included in this study. Patients with an HLA compatible sibling at diagnosis received a first-line hematopoietic stem cell transplantation (HSCT). A diagnosis of Fanconi anemia was excluded by a chromosomal breakage test. Patients with other inherited bone marrow failure syndromes were excluded from the study. h-ATG was the first choice of ATG, but r-ATG was used if h-ATG was not available. CSA was started on the first day of ATG administration and was slowly tapered (10% per month) at 12 months regardless of response status. Granulocyte-colony stimulating factor (5 μg/kg/day) was administered in the first 28 days to patients with

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antilymphocyte SerumAnemia, AplasticCyclosporineImmunosuppressive AgentsHumansChildHorsesAnimalsMaleRabbitsFemaleAdolescentChild, PreschoolTreatment OutcomeInfantRetrospective Studies

Substanzen

Antilymphocyte SerumCyclosporineImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
  • Dept. of Pediatric Hematology and Stem Cell Transplantation, Central Hospital of Southern Pest - National Institute of Hematology and Infectious Diseases, Budapest, Hungary.
  • National Children's Cancer Service, Children's Health Ireland, Dublin, Ireland.
  • Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Hearth, Rome, Italy.
  • Department of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo, Norway.

ORCID-Profile: Ayami Yoshimi, Franco Locatelli, Veerle Labarque

Förderung

  • Parent Association in Freiburg

Zitieren

APA

Yoshimi, A., Noellke, P., Starý, J., Kállay, K., Smith, O., Locatelli, F., Buechner, J., Bodova, I., Sevilla, J., Schmugge, M., Bierings, M., Masmas, T., Dworzak, M., Labarque, V., Pawelec, K., Jahnukainen, K., Polychronopoulou, S., Kjollerstrom, P., Kavcic, M., …, & Strahm, B. (2024). Comparison of outcomes of immunosuppressive therapy with rabbit versus horse antithymocyte globulin and cyclosporine a in children with acquired severe aplastic anemia. American Journal of Hematology. https://doi.org/10.1002/ajh.27334

Vancouver

Yoshimi A, Noellke P, Starý J, Kállay K, Smith O, Locatelli F, et al. Comparison of outcomes of immunosuppressive therapy with rabbit versus horse antithymocyte globulin and cyclosporine a in children with acquired severe aplastic anemia. American Journal of Hematology. 2024. doi:10.1002/ajh.27334

BibTeX
@article{Yoshimi2024,
  author = {Yoshimi, Ayami and Noellke, Peter and Starý, Jan and Kállay, Krisztián and Smith, Owen and Locatelli, Franco and Buechner, Jochen and Bodova, Ivana and Sevilla, Julian and Schmugge, Markus and Bierings, Marc and Masmas, Tania and Dworzak, Michael and Labarque, Veerle and Pawelec, Katarzyna and Jahnukainen, Kirsi and Polychronopoulou, Sophia and Kjollerstrom, Paula and Kavcic, Marko and Erlacher, Miriam and Niemeyer, Charlotte M and Strahm, Brigitte},
  title = {Comparison of outcomes of immunosuppressive therapy with rabbit versus horse antithymocyte globulin and cyclosporine a in children with acquired severe aplastic anemia},
  journal = {American Journal of Hematology},
  year = {2024},
  doi = {10.1002/ajh.27334}
}
Kostenlos starten →